Thomas M File Jr
Overview
Explore the profile of Thomas M File Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
File Jr T
Clin Chest Med
. 2025 Jan;
46(1):21-35.
PMID: 39890290
Immunocompromised patients are more susceptible to infections. Although they have reduced immune response to vaccines, it is still essential to prioritize immunizations as one strategy to potentially reduce the impact...
2.
File Jr T, Ramirez J, Wilde A
Antimicrob Agents Chemother
. 2025 Jan;
69(2):e0108724.
PMID: 39817764
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum...
3.
File Jr T, Ramirez J
N Engl J Med
. 2023 Oct;
389(17):1633-1634.
PMID: 37888934
No abstract available.
4.
5.
Paukner S, Moran G, Sandrock C, File Jr T, Vidal J, Waites K, et al.
Future Microbiol
. 2022 Mar;
17():397-410.
PMID: 35285291
What Is This Summary About?: Bacterial pneumonia is an infection of the lung caused by bacteria that is potentially deadly, costly, and affects millions of people worldwide every year. Treatment...
6.
Paukner S, Mariano D, Das A, Moran G, Sandrock C, Waites K, et al.
Antibiotics (Basel)
. 2021 Dec;
10(12).
PMID: 34943700
Lefamulin was the first systemic pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia based on two phase 3 trials (Lefamulin Evaluation Against Pneumonia [LEAP]-1...
7.
Paukner S, Goldberg L, Alexander E, Das A, Heinrich S, Patel P, et al.
J Glob Antimicrob Resist
. 2021 Nov;
29:434-443.
PMID: 34788694
Objectives: Lefamulin, a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia (CABP), was evaluated for microbiological efficacy in a prespecified pooled analysis of LEAP 1 and 2 phase 3 clinical trial...
8.
File Jr T, Alexander E, Goldberg L, Das A, Sandrock C, Paukner S, et al.
BMC Pulm Med
. 2021 May;
21(1):154.
PMID: 33964925
Background: Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP)...
9.
Cornely O, File Jr T, Garrity-Ryan L, Chitra S, Noble R, McGovern P
Int J Antimicrob Agents
. 2020 Dec;
57(2):106263.
PMID: 33326848
Background: Many antibiotics require dosage adjustments in patients with renal impairment. In Phase III studies, omadacycline was non-inferior to moxifloxacin and linezolid in adults with community-acquired bacterial pneumonia (CABP) and...
10.
File Jr T, Jump R, Goff D
Infect Dis Clin North Am
. 2020 Nov;
34(4):903-920.
PMID: 33131574
This article summarizes the literature describing how antimicrobial stewardship and telemedicine interventions affect antimicrobial resistance. Discussion includes why we need stewardship, how to collaborate with team members, and the evidence...